An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937

Papulopustular Rosacea Erythematotelangiectatic Rosacea

COMPLETED PHASE3

A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

NCT01513863

Rosacea

COMPLETED PHASE1

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

NCT01139008

Skin Manifestations

COMPLETED PHASE4

Metronidazole SC Penetrance With Moisturizers

NCT06434519

Rosacea, Erythematotelangiectatic

COMPLETED NA

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269

Rosacea

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluate the relationship between treatment with MetroGel® 1% and cosmetic performance with the Subjects' usual cosmetic products. It is expected that the female subjects will be able to use their routine cosmetics after application without affecting the cosmetic product's performance or causing side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rosacea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea

Metronidazole Gel

Intervention Type DRUG

Topical, Once daily for 2 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metronidazole Gel

Topical, Once daily for 2 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MetroGel® 1%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with moderate Rosacea (Global Severity Score of 3),
* Subjects willing to stop their current rosacea medication for at least 2 weeks
* Subjects must have an established routine of cosmetics application (e.g. must have been using the same facial foundation for at least 3 months and it is not expected to change during the study)
* Subjects must be willing to use their routine facial foundation and not change products while on study

Exclusion Criteria

* Subjects who do not routinely wear facial foundation
* Subjects who failed to undergo a washout period of 14 days for the use of topical rosacea therapy, (for example: metronidazole, azelaic acid, sulfacetamide)
* Subjects who are unwilling to stop their current rosacea medications for 2 weeks

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No